drugset / Trial / NCT05544526
CAR T Cells to Target GD2 for DMG
NaSingle-groupOpen-labelTreatment
Summary
The CARMIGO Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and young adults aged 2-16 years with Diffuse Midline Glioma (DMG). The study will evaluate the feasibility of generating the ATIMP, the safety and tolerability of the GD2CAR T-cell therapy and how effectively GD2CAR T-cells engraft, expand and persist following administration in patients with DMG.
Timeline
- Start
- 2023-08-15
- Primary completion
- 2025-12
- Completion
- 2039-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GD2 CAR T cells | Cell therapy | 3e+07 unknown | Intravenous |
| Subject | GD2 CAR T cells | Cell therapy | 1e+08 unknown | Intravenous |
| Subject | GD2 CAR T cells | Cell therapy | 3e+08 unknown | Intravenous |